Dec 19 (Reuters) - Antisense Therapeutics Ltd (ANP) :
- CLINICAL TRIAL APPLICATION SUBMITTED FOR ATL1102 PHASE IIB DMD TRIAL CONDUCT IN EUROPE
- CTA APPROVALS ARE EXPECTED TO COME THROUGH IN A STAGGERED MANNER IN EARLY 2023
News: ANP Antisense Therapeutics Submits Clinical Trial Application For Atl1102 Phase Iib Dmd Trial...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.1¢ |
Change
0.002(22.2%) |
Mkt cap ! $11.96M | |||
| Open | High | Low | Value | Volume |
| 1.0¢ | 1.3¢ | 1.0¢ | $215.5K | 19.86M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 11300000 | 1.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.1¢ | 800000 | 3 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| PER (ASX) Chart |